PAH News

April 12, 2018April 12, 2018

Genetic Landscape of PAH Differs Between Children and Adults, Study Shows

News, PAH News

The genetic landscape of pulmonary arterial hypertension that strikes in childhood differs from the one that develops after a person reaches adulthood, a study reports. There is little variation ... Read more

April 9, 2018April 9, 2018

Traditional Chinese Medicine Shows Promise for Treating PAH, Study Reports

News, PAH News

A compound in a plant that is used in traditional Chinese medicine lowered the lung blood pressure of rats with pulmonary arterial hypertension, a study shows The compound, osthole, did ... Read more

April 4, 2018April 4, 2018

PAH Patient Outcomes Linked to Exercise Capacity

journals.plos.org

March 23, 2018April 1, 2018

Bardoxolone Methyl Improves Exercise Capacity of PH Patients with ILD in Phase 2 Trial

News, PAH News

Bardoxolone methyl, Reata Pharmaceuticals’ treatment candidate for pulmonary hypertension (PH), improves exercise capacity and has a safe profile in patients with PH associated with interstitial lung disease (ILD), according to ... Read more

March 21, 2018March 21, 2018

Low Levels of Enzyme Lead to Calcium Deposits in Hypoxic PAH, Animal Study Shows

News, PAH News

Deficiency of an enzyme called granzyme B leads to deposits of calcium in pulmonary blood vessels, contributing to the defects found in hypoxic pulmonary arterial hypertension (PAH), an animal ... Read more

March 19, 2018March 19, 2018

Bellerophon Is Advancing Its PH Treatment INOpulse Through Clinical Trials

News, PAH News, PH News

Bellerophon Therapeutics is advancing the clinical trials program of its inhaled INOpulse nitric oxide therapy for pulmonary hypertension (PH) associated with several lung diseases. The company is developing INOpulse for patients ... Read more

March 16, 2018March 16, 2018

Cardiome Shares Updates on Therapies, Including Trevyent for PAH

News, PAH News

Cardiome recently shared an update on the development of its therapeutic portfolio, including Trevyent (treprostinil injection) for the treatment of pulmonary arterial hypertension (PAH). Following the U.S. Food and Drug Administration’s ... Read more

March 15, 2018March 15, 2018

Reviva’s Pulmonary Hypertension Therapy Works Even Better in Combos, Study Shows

News, PAH News

Combinations of Reviva Pharmaceuticals’ RP5063 and other pulmonary arterial hypertension treatments improved rats’ lung blood vessel structure and lung function, a study reports. Previous research in rats indicated that RP5063 could ... Read more

March 9, 2018March 9, 2018

MannKind Starting Enrollment of Phase 1 Trial Testing Powdered Treprostinil for PAH

News, PAH News

MannKind Corporation will start enrollment for a Phase 1 trial to test its treprostinil inhaled therapy for the treatment of pulmonary arterial hypertension (PAH). The trial will be conducted under ... Read more

March 8, 2018March 8, 2018

Quebec Province Agrees to Public Health Insurance Coverage of PAH Therapy Uptravi

News, PAH News

Canada’s Quebec Province has agreed to provide public health insurance coverage of Actelion‘s pulmonary arterial hypertension therapy Uptravi (selexipag). The pan-Canadian Pharmaceutical Alliance (pCPA), a group that represents Canada’s provinces ... Read more

Pin It on Pinterest